K-41
K-41 is an orally active antibiotic. K-41 can be obtained from Streptomyces hygroscopicus. K-41 has antibacterial and antiplasmodial activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 53026-37-2
- 分子式: C48H82O18
- 分子量:947.15
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-N0402S
Artemether-d3Stable Isotope -
HY-G0016
N-Acetyl dapsoneDapsone Metabolite -
HY-N3300
MelleinNatural Product -
HY-124452
NocardamineSiderophore -
HY-N1584B
Halofuginone hydrochlorideNatural Product -
HY-W196368
ThymohydroquinoneCOX-2 Inhibitor -
HY-125049
KijanimicinAntibiotic -
HY-N7536
VoacangineTRPM8 Antagonist -
HY-113784
ThiocarlideAntibacterial Agent -
HY-N8373
Beauvericin AAntibacterial Agent -
HY-N1584BR
Halofuginone hydrochloride (Standard)Reference Standard -
HY-123635
NybomycinAntibiotic
生物活性
製品説明
体外実験
K-41 inhibits K1 and FCR3 strains of Plasmodium falciparum, with IC50s of 8.5 and 31 nM[1].
K-41 inhibits B. subtilis, B. anthracis, S. aureus, S. pyogenes, S. pneumonia, C. diphtheria, and M. tuberculosis, with MICs of 3.13, 1.56, 1.56, 0.78, 0.39, 0.78, and 3.13 µg/mL, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
化学情報
-
CAS 番号 53026-37-2
-
分子量 947.15
-
分子式 C48H82O18
-
SMILES
C[C@H]([C@H]1OC)[C@](O[C@@H](C2)C[C@H](O[C@]3(O)[C@@H](O)C(O)=O)[C@@](C)([C@H]([C@@H]3C)OC)OC)([C@@H]([C@@H]2OC)C)O[C@@]1([C@]4([H])O[C@@]([C@]5([H])O[C@]([C@](O[C@@]6(O)C)([H])[C@H]([C@@H]([C@H]6C)O[C@@H](CC[C@@H]7OC)O[C@@H]7C)C)([H])CC5)([H])CC4)C
-
Structure Classification
-
Initial Source
germ
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
[1]. Otoguro K, et al. In vitro and in vivo antimalarial activities of the monoglycoside polyether antibiotic, K-41 against drug resistant strains of Plasmodia. J Antibiot (Tokyo). 2002 Sep;55(9):832-4. [Content Brief]
[2]. Tsuji N, et al. Two new antibiotics, A-218 and K-41. Isolation and characterization. J Antibiot (Tokyo). 1976 Jan;29(1):10-4. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
K-41 関連分類
HY-136943 関連分類
Powered by Bioz